SCHEMBL7007325

SCHEMBL7007325

C=CCSCCCN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL898058 0.83
SCHEMBL3479376 0.83 ALOX5 (0.62)
Hydrochloric Acid SCHEMBL8604712 0.81
SCHEMBL3479153 0.80 ALOX5 (0.59)
SCHEMBL4157460 0.80 ALOX5 (0.59)
SCHEMBL3479692 0.80 ALOX5 (0.59)
SCHEMBL10824237 0.76 ALOX5 (0.71)
SCHEMBL7053908 0.76
SCHEMBL11216419 0.76
SCHEMBL4529352 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-3950542-A Cysteamine derivatives for oral treatment of seborrhea L'OREAL (FR) 1976-04-13 US claimed
US-20230404947-A1 COMPOSITIONS, METHODS OF TREATMENT, AND CONTAINERS INCLUDING COMPOSITIONS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2023-12-21 US disclosed
US-20230338310-A1 ANTI-VIRAL THERAPY NOVABIOTICS LIMITED (GB) 2023-10-26 US disclosed
US-11771665-B2 Compositions, methods of treatment, and containers including compositions UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2023-10-03 US disclosed
EP-4157247-A1 ANTI-VIRAL THERAPY Novabiotics Limited (GB) 2023-04-05 EP disclosed
US-20220347126-A1 COMPOSITIONS, METHODS OF TREATMENT, AND CONTAINERS INCLUDING COMPOSITIONS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2022-11-03 US disclosed
US-11406607-B2 Compositions, methods of treatment, and containers including compositions UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2022-08-09 US disclosed
US-11369568-B2 Microparticles comprising a sulphur-containing compound NOVABIOTICS LIMITED (GB) 2022-06-28 US disclosed
WO-2021240145-A1 ANTI-VIRAL THERAPY NOVABIOTICS LIMITED (GB) 2021-12-02 WO disclosed
WO-2021203136-A1 METHODS FOR TREATING HYPERPIGMENTATION AND COMPOSITIONS FOR SAME CHEMISTRYRX (US) 2021-10-07 WO disclosed
EP-3197476-A1 USE OF CYSTEAMINE IN TREATING INFECTIONS CAUSED BY YEASTS/MOULDS Novabiotics Limited (GB) 2017-08-02 EP disclosed
WO-2016198842-A1 AN AMINO THIOL FOR USE IN THE TREATMENT OF AN INFECTION CAUSED BY THE BACTERIUM MYCOBACTERIUM SPP. NOVABIOTICS LIMITED (GB) 2016-12-15 WO disclosed
US-20160102052-A1 Use of Cysteamine in Treating Infections caused by Yeasts/Moulds NOVABIOTICS LIMITED (GB) 2016-04-14 US disclosed
WO-2016046524-A1 USE OF CYSTEAMINE IN TREATING INFECTIONS CAUSED BY YEASTS/MOULDS NOVABIOTICS LIMITED (GB) 2016-03-31 WO disclosed
EP-1314736-A2 Silicone monomers and oligomers having a carboxyl functional group thereon MONA INDUSTRIES, INC. (US) 2003-05-28 EP disclosed
EP-0951468-A4 SILICONE MONOMERS AND OLIGOMERS HAVING A CARBOXYL FUNCTIONAL GROUP THEREON MONA INDUSTRIES INC (US) 2001-06-06 EP disclosed
EP-0951468-A1 SILICONE MONOMERS AND OLIGOMERS HAVING A CARBOXYL FUNCTIONAL GROUP THEREON MONA INDUSTRIES, INC. (US) 1999-10-27 EP disclosed
US-5919938-A Silicone monomers and oligomers having a carboxyl functional group thereon MONA INDUSTRIES, INC. (US) 1999-07-06 US disclosed
US-5780639-A COUPLING AGENTS, ADHESION PROMOTERS, CROSSLINKING AGENTS MONA INDUSTRIES, INC. (US) 1998-07-14 US disclosed
WO-1998022478-A1 SILICONE MONOMERS AND OLIGOMERS HAVING A CARBOXYL FUNCTIONAL GROUP THEREON MONA INDUSTRIES, INC. (US) 1998-05-28 WO disclosed